Trial · NCT05816720
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival | Up to approximately 11 years | Time from the index date of treatment or re-treatment with lutetium-177 DOTATATE until the date of progression or death |
| Primary | Overall survival | Up to approximately 11 years | Time from the index date of treatment or re-treatment with lutetium-177 DOTATATE until the date of death |
| Primary | Percentage of patients with treatment response | Up to approximately 11 years | Best overall response was defined per Response Evaluation Criteria In Solid Tumors (RECIST), 1.1. Overall response: complete response (CR) + partial response (PR); CR; PR; stable disease (SD); and progressive disease (PD) |
| Secondary | Number of patients with adverse events (AEs) | Up to approximately 11 years | |
| Secondary | Mean change from baseline in white blood cell (WBC) count | Up to approximately 11 years | |
| Secondary | Mean change from baseline in hemoglobin | Up to approximately 11 years | |
| Secondary | Mean change from baseline in absolute neutrophil count (ANC) | Up to approximately 11 years | |
| Secondary | Mean change from baseline in lymphocyte count | Up to approximately 11 years | |
| Secondary | Mean change from baseline in platelet count | Up to approximately 11 years | |
| Secondary | Mean change from baseline in alkaline phosphatase (ALP) | Up to approximately 11 years | |
| Secondary | Mean change from baseline in alanine aminotransferase (ALT) | Up to approximately 11 years | |
| Secondary | Mean change from baseline in aspartate aminotransferase (AST) | Up to approximately 11 years | |
| Secondary | Mean change from baseline in albumin | Up to approximately 11 years | |
| Secondary | Mean change from baseline in bilirubin | Up to approximately 11 years | |
| Secondary | Mean change from baseline in creatinine | Up to approximately 11 years | |
| Secondary | Mean change from baseline in estimated glomerular filtration rate (eGFR) | Up to approximately 11 years | |
| Secondary | Mean change from baseline in cromogranin A | Up to approximately 11 years | |
| Secondary | Mean change from baseline in pancreatic polypeptide | Up to approximately 11 years | |
| Secondary | Mean change from baseline in pancreastatin | Up to approximately 11 years | |
| Secondary | Number of patients who received other treatments prior to initial treatment with lutetium-177 DOTATATE | Prior to initial treatment with lutetium-177 DOTATATE |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05816720/registered